US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of ...
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback